# International Journal <br> PHARMACEUTICAL SCIENCES <br> AND <br> Research 

Received on 30 May, 2011; received in revised form 06 August, 2011; accepted 28 September, 2011

# NOVEL METHODS FOR THE VISIBLE SPECTROPHOTOMETRIC DETERMINATION OF PIPAZETHATE HCI AND CHLORPHENOXAMINE HCI IN PURE AND TABLET DOSAGE FORMS 

Ali M. Hassan ${ }^{1}$, Ahmed F. El-Asmy ${ }^{2}$, Yasser B. Abd El-Raheem ${ }^{* 3}$<br>Department of Inorganic and Analytical Chemistry, Faculty of Science, Al-Azhar University ${ }^{1}$, Cairo, Egypt Department of Inorganic and Analytical Chemistry, Faculty of Science, Al-Mansoura University ${ }^{2}$, Egypt Forensic Chemist, Medico-Legal organization, Ministry of Justice ${ }^{3}$, Cairo, Egypt

## Keywords:

 Spectrophotometry, Pipazethate hydrochloride, Chlorphenoxamine hydrochloride,Picric acid,
Phenol red, Chlorophenol red, Tablet dosage forms

Correspondence to Author:

Yasser B. Abd El-Raheem

Forensic Chemist, Medico-Legal organization, Ministry of Justice, Cairo, Egypt


#### Abstract

Three rapid, simple, precise and sensitive visible spectrophotometric methods (A-C) have been developed for the determination of pipazethate hydrochloride ( $\mathrm{PZ}-\mathrm{HCl}$ ) and Chlorphenoxamine hydrochloride ( $\mathrm{CPA}-\mathrm{HCl}$ ) in pure and Tablet Dosage Forms. Both methods (A-C) involves the formation of intense yellow ion-association complex between drug(s) and either of picric acid (PA) or phenol red (PR) or chlorophenol red (CPR) reagents followed by extraction with methylene chloride. The ion-associates exhibit absorption maxima at 359,393 and 405 nm for $\mathrm{PZ}-\mathrm{HCl}$ and at 357,388 and 400 nm for CPA-HCl with PA, PR and CPR, respectively. The calibration curves resulting from the measurements of absorbance-concentration relations (at the optimum reaction conditions) of the extracted ion-association complexes are linear over the concentration range 3.05-43.60, 8.72-104.64 and 3.27-49.05 $\mu \mathrm{g} / \mathrm{mL}$ for $\mathrm{PZ}-\mathrm{HCl}$ and 3.40-47.64, 8.51-88.48 and $3.40-40.84 \mu \mathrm{~g} / \mathrm{mL}$ for CPAHCl with PA, PR and CPR, respectively. The molar absorptivities and Sandell's sensitivities of the reaction products were calculated. In methods (A-C) the slope, intercept, correlation coefficient, relative standard deviation (RSD), detection and quantitation limits were also calculated. No interference was observed from common excipients present in pharmaceutical formulations. The results are well compared to those obtained by the reference methods using Students t- and F-tests. Therefore, the present methods are suitable for the drugs determination, as they are accurate and precise to a high extent.


INTRODUCTION: Pipazethate hydrochloride (PZ-HCl) (Fig. 1) ${ }^{1}$, chemically, it is 2-(2-Piperidinoethoxy)ethyl pyrido[3, 2- b][1, 4]benzothiazine- 10- carboxylate hydrochloride ${ }^{2}$. Medically, it is a centrally acting cough suppressant which also has some peripheral actions in non-productive cough. It has a bronchodilator effect which reduces the increased resistance to expiration during paroxysms of cough.


FIG. 1: CHEMICAL STRUCTURE OF PZ-HCI

In recent years, a very few analytical methods appeared in the literature for the determination of PZHCl in various types of samples such as highperformance liquid chromatography (HPLC) ${ }^{3}$, visible spectrophotometry ${ }^{4,5}$ and electrochemical method such as conductimetric method ${ }^{6}$. These methods involve a time-consuming extraction procedures or heating and require strictly con trolled reaction conditions. Many of these methods are less sensitive.

Chlorphenoxamine hydrochloride (CPA-HCl) (Fig. 2), ${ }^{1}$ chemically, it is 2-(4-Chloro- $\alpha$-methylbenzhydryloxy)-NN-dimethylethylamine hydrochloride ${ }^{2}$. Medically, it has antimuscarinic and antihistaminic properties. It has been used in nausea, vomiting, and vertigo, and was formerly used in the symptomatic treatment of parkinsonism.


FIG. 2: CHEMICAL STRUCTURE of CPA-HCI
In recent years, a few analytical methods have been reported on the determination of $\mathrm{CPA}-\mathrm{HCl}$ in Pure and in tablet dosage forms such as Thin layer chromatography (TLC) (densitometric method) ${ }^{7}$, UV/visible spectrophotometry ${ }^{8-12}$, Atomic-absorption spectrometry (AAS) ${ }^{13}$ and electrochemical method such as Polarographic method ${ }^{14}$. These methods are time-consuming, expensive costly, complicated and require strictly con trolled reaction conditions. Many of these methods are less sensitive.

Thus, the aim of the present work was to investigate economical, simple, precise, sensitive and environmental friendly three analytical methods (A-C) for the determination of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ using visible spectrophotometry. Both methods (A-C) involves the formation of intense yellow ionassociation complex between drug(s) and either of picric acid (PA) or phenol red (PR) or chlorophenol red (CPR) reagents by extraction with proper water-
immiscible organic solvent. The results obtained from the proposed methods also have been statistically compared using Students t - and F -tests to the reference methods. They also have the advantage of being cheaper than the reported methods.

## Experimental:

Materials and Reagents: PZ-HCl and CPA-HCl standards were kindly supplied as a gift samples by Egyptian International Pharmaceutical Industries Co. Cairo, Egypt (E.I.P.I.CO.) and used without further purification and purity was confirmed by thin layer chromatography and by melting point measurements. Commercial tablets of Pipazethate hydrochloride such as Selgon tablets containing 20 mg pipazethate hydrochloride and Allergex tablets containing 20 mg chlorphenoxamine hydrochloride were purchased from local drug market. Picric acid (PA) reagent (Fig. 3) from Arablab chemicals, phenol red (PR) (Fig. 4) and chlorophenol red (CPR) (Fig. 5) reagents from Merck chemicals. All other chemicals, solvents and reagents used were obtained from commercial sources and were of analytical reagent grade. Doubly distilled water was used throughout for final washings and preparations of all aqueous solutions. Freshly prepared solutions were always employed.


FIG. 3: CHEMICAL STRUCTURE OF PA


FIG. 4: CHEMICAL STRUCTURE OF PR


FIG. 5: CHEMICAL STRUCTURE OF CPR
Instruments and apparatus: All spectrophotometric measurements were carried out by using UV-Visible Diode Array spectrophotometer (Hewlett PackardModel 8452A), in 1.0 cm quartz cells, was connected to PC computer and Hewlett Packard DeskJet printer. The pHs of the prepared solutions were adjusted using Jenway pH-meter. Moreover, the doubly distilled water was obtained ELGA apparatus model, UHQ-IIMK3, UK. Temperature adjustment during experiments was carried out with controlled temperature Water Bath (MLW) Model, W11-TGL, GBR. Automatic Pipettes were used to measure the very small volumes whereas glass micropipettes and burettes were used to measure the large volumes.

Preparation of Standard Solutions: For methods A, B and C , standard stock solutions 0.01 M of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ were freshly prepared by dissolving the appropriate weights of $1.09 \mathrm{~g}(\mathrm{PZ}-\mathrm{HCl})$ and 0.8508 g (CPA-HCI) in least amount of warm water then the solutions were made up to 100 mL with distilled water. Successive dilutions were prepared for carrying out the subsequent studies.

Standard stock solution 0.01 M of PA was freshly prepared by dissolving the appropriate weight of 0.5728 g in least amount of warm water then the solution was made up to 100 mL with distilled water. Successive dilutions were prepared for carrying out the subsequent studies. Similarly, standard stock solutions 0.01 M of PR and CPR were freshly prepared by dissolving the appropriate weights of ( 0.8860 g and 1.0582 g , respectively), in least amount of methanol then the solutions were made up to 100 mL with distilled water. Successive dilutions were prepared for carrying out the subsequent studies.

Recommended Procedures for the determination of PZ-HCl and CPA-HCl (Calibration Standards): For method A, B and C, 2.5 mL of 0.001 M (PA or CPR) or 0.005 M PR were added in acid medium to a solution of PZ-HCl using the concentration range of 3.05-43.60 $\mu \mathrm{g} / \mathrm{mL}$ (PA), 3.27-49.05 $\mu \mathrm{g} / \mathrm{mL}$ (CPR) and 8.72-104.64 $\mu \mathrm{g} / \mathrm{mL}$ (PR) of $\mathrm{PZ}-\mathrm{HCl}(\mathrm{n}=5)$ were transferred into a series of 125 mL separating funnels. Methylene chloride ( 10 mL ) was added to each of the separating funnel, the contents were shaken well for two minutes and left at room temperature for a minute. The two phases were allowed to separate and the methylene chloride layer was passed through anhydrous sodium sulphate.

The absorbances of the yellow ion-association complexes were measured at 359,393 and 405 nm for PA, PR and CPR, respectively, against corresponding reagent blank. This blank was prepared in the same manner without the addition of PZ-HCl. A calibration curves were plotted (Fig. 20).

In a similar way, 2.5 mL of 0.001 M (PA or CPR) or 0.005 M PR were added in acid medium to a solution of CPA-HCl within concentration range of 3.4-47.64 $\mu \mathrm{g} / \mathrm{mL}$ (PA), 3.4-40.84 $\mu \mathrm{g} / \mathrm{mL}$ (CPR) and 8.51-88.48 $\mu \mathrm{g} / \mathrm{mL}$ (PR) of CPA-HCl ( $\mathrm{n}=5$ ). Using the same procedures described for PZ-HCl. The absorbance of the extract was measured at $\lambda_{\text {max }} 357,388$ and 400 nm for PA, PR and CPR, respectively, against corresponding reagent blank. A calibration curves were plotted (Fig. 21). The results of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ ion-associates with PA or PR or CPR correlated to Beer's law are presented in Table 2.

Determination of PZ-HCl and $\mathrm{CPA}-\mathrm{HCl}$ in tablets: For methods A, B and C, ten tablets of selgon and allergex were accurately weighed separately and finely powdered and mixed. A portion of the powder equivalent to the average weight of one tablet was transferred into a 100 mL volumetric flask and 30 mL of distilled water was added. The content of the flask was sonicated for 15 min . and filtered through Whatmann No. 41 filter paper to separate out the insoluble excipients. The residues were washed thoroughly with distilled water. Then take aliquot of the filtrate made up to 100 mL volume with distilled water in volumetric flask.

Appropriate solutions were prepared by taking suitable aliquots of the clear supernatant and diluting them with distilled water to give final concentrations.

Then the absorbance of these solutions was measured against reagent blank at $\lambda_{\text {max }}$. The amount of PZ- HCl or CPA-HCl per tablet was calculated using the calibration curve method. A standard addition method was also used to confirm the accuracy and recoveries.

RESULTS AND DISCUSSION: Both methods (A-C) involves the formation of intense yellow ionassociation complex between drug(s) and either of PA or PR or CPR reagents followed by extraction with methylene chloride. Many drugs are easy to be determined by spectrophotometry based on color. Optimum reaction conditions for quantitative determination ion-association complexes of PZ-HCl and CPA-HCl with PA, PR and CPR reagents, respectively, were established via a number of following preliminary experiments.

Selection of suitable Wavelength: The absorption spectra of the formed ion-association complexes were measured in the visible region within 300-700 nm wavelength range against blank reagent prepared in the same manner without the addition of the drug. The $\mathrm{PZ}-\mathrm{HCl}$ ion-associates with PA, PR and CPR reagents, $\lambda_{\max }$ of 359, 393 and 405 nm have been obtained, respectively as shown in Fig. 6. For $\mathrm{CPA}-\mathrm{HCl}$ ionassociates, $\lambda_{\max }$ of 357,388 and 400 nm with PA, PR and CPR reagents have been obtained, respectively as shown in Fig. 7.


FIG. 6: ABSORPTION SPECTRA OF PZ-HCI ION-ASSOCIATES WITH PA, PR AND CPR


FIG. 7: ABSORPTION SPECTRA OF CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

Effect of extracting solvents: The polarity of the solvent affects both extraction efficiency and absorpitivity of the ion-associates. Therefore, several water-immiscible organic solvents including $n$-hexane, petroleum ether, cyclohexane, carbon tetrachloride, toluene, benzene, diethyl ether, methylene chloride and chloroform were investigated.

The most convenient solvent for $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ ion associates which exhibit the maximum absorbance, high extraction power and stable colours is methylene chloride.

In all cases the aqueous to organic phase ratio of 1:1.5 was the most suitable for the ion-associate extraction. Complete extraction was attained by using single portion of 10 mL solvent upon using the above reagents. Fig. 8 and 9 summarize the effect of extracting solvents on the formed ion-associates.


FIG. 8: EFFECT OF EXTRACTING SOLVENTS ON PZ-HCI IONASSOCIATES WITH PA, PR AND CPR


FIG. 9: EFFECT OF EXTRACTING SOLVENTS ON CPA-HCI IONASSOCIATES WITH PA, PR AND CPR

Effect of pH : To investigate the optimum medium conditions to determine $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$, quantitatively the effect of pH was studied by using a series of solutions $(\mathrm{HCl} / \mathrm{NaOH})$ in the pH range of 1-14, for developing the best color of drug-reagent ionassociates against the chosen reagents. In PZ-HCl and $\mathrm{CPA}-\mathrm{HCl}$, the optimum pH range for complete formation of the ion-associates showed that highest absorbance values, at their respective $\lambda_{\max }$ were found to be in the ranges 2-4 for PA, 2-6 for PR and 2-5 with CPR, as shown in Figs. 10 and 11, respectively.

At pH less than 2 for $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{PZ}-\mathrm{HCl}$, the absorbance decrease may be attributed to the formation of diprotonated species of the drug. In case of $\mathrm{pH}>4$ or $\mathrm{pH}>6$ or $\mathrm{pH}>5$ the absorbance decrease due to the formation of free base of the drug(s) which are insoluble in water and precipitates during the mixing.

## Effect of pH on PZ-HCl ion-ass ociates with PA. PR and CPR



FIG. 10: EFFECT OF PH ON PZ-HCI ION-ASSOCIATES WITH PA, PR AND CPR


FIG. 11: EFFECT OF PH ON CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

Effect of Reagent Concentration: The effect of reagent concentration was tested by using varying amounts (16) mL of 0.005 M (PR or CPR) with 1 mL of $0.001 \mathrm{M} \mathrm{PZ-}$ HCl and 0.001 M PA with 1 mL of $0.0002 \mathrm{M} \mathrm{PZ-HCl}$ and 0.001 M (PA or CPR) with 1 mL of $0.0002 \mathrm{M} \mathrm{CPA}-\mathrm{HCl}$ and 0.005 M PR with 1 mL of $0.001 \mathrm{M} \mathrm{CPA}-\mathrm{HCl}$. After implementing the optimum pH condition for $\mathrm{PZ}-\mathrm{HCl}$ and CPA-HCl, the formed ion-associate was completely extracted with single portion of 10 mL methylene chloride. The mixture was shaked for 2 minutes. The results showed that 5 mL of 0.005 M (PA or PR or CPR) were sufficient for good color intensity with maximum absorption of the investigated ion-associates.

Effect of Time: Under the above mentioned conditions the effect of time on the formation of the ionassociates was studied by measuring absorbance of the extracted ion-associates with increasing time intervals. The results showed that the ion-associates are formed almost instantaneously.

The effect of time on the stability of the ion-associates of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ are represented graphically in Fig. 12 and 13, respectively. For PZ-HCl, the developed color remained stable for 21, 21 and 18 hours for PA, PR and CPR at $\lambda_{\max }$ of 359, 393 and 405 nm , respectively. Similarly, the ion-associates of CPA-HCl are formed almost instantaneously. Moreover, the developed color for CPA-HCl remained stable for 24, 18 and 21 hours for PA, PR and CPR, at $\lambda_{\max }$ of 357,388 and 400 nm , respectively. After these intervals, a decrease in color intensity occurred in ion associated of $\mathrm{PZ}-\mathrm{HCl}$ and CPA-HCl.


FIG. 12: EFFECT OF TIME ON THE STABILITY OF PZ-HCI IONASSOCIATES WITH PA, PR AND CPR


FIG. 13: EFFECT OF TIME ON THE STABILITY OF CPA-HCI IONASSOCIATES WITH PA, PR AND CPR

Effect of Temperature: Under afore mentioned conditions (solvents, pH , reagent concentration and time), the effect of temperature on the formation of the ion-associates was studied by measuring the absorbance of the extracted ion-associates at a temperature range of $25-90^{\circ} \mathrm{C}$.

For PZ-HCl, the results showed that the ion-associates are formed almost instantaneously in all cases at room temperature $25 \pm 5^{\circ} \mathrm{C}$ and remain constant up to $45^{\circ} \mathrm{C}$, $40^{\circ} \mathrm{C}$ and $55^{\circ} \mathrm{C}$ for PA, PR and CPR, respectively as represented by its absorptivity at the recommended ( $\lambda_{\text {max }}$ ). Similarly, the ion-associates of CPA-HCl are formed instantaneously with all reagents at room temperature $25 \pm 5^{\circ} \mathrm{C}$ and remain constant up to $50^{\circ} \mathrm{C}$, $45^{\circ} \mathrm{C}$ and $45^{\circ} \mathrm{C}$ for PA, PR and CPR, respectively. The effect of temperature on the stability of ion-associates of PZ-HCl and CPA-HCl are shown in Figs. 14 and 15, respectively.


FIG. 14: EFFECT OF TEMPERATURE ON THE STABILITY OF PZ-HCI ION-ASSOCIATES WITH PA, PR AND CPR


FIG. 15: EFFECT OF TEMPERATURE ON THE STABILITY OF CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

The Stoichiometry of the lon- Associates: Aided by spectrophotometeric measurements, the stoichiometries of the ion-associates of PZ-HCl and CPA-HCl with selected reagents were investigated by the aid of the following spectrophotometeric.

The Molar Ratio Method: The molar ratio method was described by Yoe and Jones ${ }^{15}$. At the optimum conditions described earlier for PZ-HCl and CPA-HCl ion-associates with their proper reagents, a series of solutions were prepared in which the reagent contents was kept constant, while that of the drug regularly varied. The absorbancies of the resultant extracts were measured at the corresponding $\lambda_{\max }$ of the ionassociates. The absorbance values were plotted against the molar ratio of drug/reagent as shown in Figs. 16 and 17, respectively. Two straight lines were intersecting at the molar ratio of 1 in case of PA, PR and CPR which reflects the formation of 1:1 ratio of (drug: reagent) for all ion-associates.


FIG. 16: MOLAR RATIO OF PZ-HCI ION-ASSOCIATES WITH PA, PR AND CPR [D=DRUGS AND R=REAGENTS]


FIG. 17: MOLAR RATIO OF CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR [D=DRUGS AND R=REAGENTS]

The Continuous Variation Method: The modification of Job's ${ }^{16}$ continuous variation method performed by Vosburgh and Cooper ${ }^{17}$ was utilized for investigating the reaction between drug and reagent. A series of solutions was prepared by mixing equimolar solutions of the drug and reagent in varying proportions while keeping the total molar concentration constant. The absorbance spectra of the resultant extracts were measured at the respective $\lambda_{\text {max }}$ of the ion-associates to determine the absorbance. Then a plot of the absorbance against the mole fraction of the drug was constructed and presented graphically in Fig. 18 and 19 , respectively.

The curves exhibit a maximum at mole fraction 0.5 with PA, PR and CPR indicating the formation of 1:1 (drug: reagent) for the proposed ion-associates.


FIG. 18: CONTINUOUS VARIATION OF PZ-HCI ION- ASSOCIATES WITH PA, PR AND CPR


FIG. 19: CONTINUOUS VARIATION OF CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

Probable reaction mechanism for the formation of Ion-Association Complexes: In the first, aided by Chem Draw Ultra (Cambridge Soft Chem. Office, Ultra 2006 Versions 10.0), equipped with additional GAMES software ${ }^{18,19}$, the structures of positive protonated nitrogen atom of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ compounds were proposed. In the second, the nature of the binding of reagents to each drug in the presence of equal amount of PA or PR or CPR was determined by the molar ratio 15 and the continuous variation methods ${ }^{16,17}$. The results indicated that a 1:1 ratio of (drug: reagent) for all ion-associates are formed as shown in Fig. 16-19.

Found that PZ-HCl and CPA-HCl reacts with PA or PR or CPR forming ion-associated compounds through the electrostatic attraction between positive protonated nitrogen atom of $\mathrm{PZH}^{+}$and $\mathrm{CPAH}^{+}$and $\mathrm{PA}^{-}$or $\mathrm{PR}^{-}$or CPR ${ }^{-}$anions. Charts 1 and 2 summarize probable reaction mechanism for the formation of ionassociation complexes of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ with PA or PR or CPR.



PZH ${ }^{+}$

CHART 1: PROBABLE REACTION MECHANISM FOR THE FORMATION OF ION-ASSOCIATION COMPLEXES OF PZH ${ }^{+}$WITH PA ${ }^{-}$, PR AND CPR


CPAH ${ }^{+}$

TABLE 1: OPTIMAL CONDITION FOR THE EXTRACTION OF PZ-HCI AND CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

| Parameters | PZ-HCl |  |  | CPA-HCl |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | PZ-PA | PZ-PR | PZ-CPR | CPA-PA | CPA-PR | CPA-CPR |
| $\lambda$ max, nm | 359 | 393 | 405 | 357 | 388 | 400 |
| Extracting solvents | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ | $\mathrm{Cl}_{2} \mathrm{CH}_{2}$ |
| Colour of extract | Yellow | Yellow | Yellow | Yellow | Yellow | Yellow |
| pH range | 2-4 | 2-6 | 2-5 | 2-4 | 2-6 | 2-5 |
| Stability of extracts, h . | 21 | 21 | 18 | 24 | 18 | 21 |
| Temperature on the stability, ${ }^{\circ} \mathrm{C}$ | 45 | 40 | 55 | 50 | 45 | 45 |
| The stoichiometry of the ion-associates | 1:1 | 1:1 | 1:1 | 1:1 | 1:1 | 1:1 |

Validity of the Beer's Lambert Law: The spectrophotometric determination of PZ-HCl and CPAHCl were carried out using appropriate concentration range to ensure the obedience to Beer's law. The obedience of absorbance PZ-HCl ion-associates with PA, PR and CPR to Beer's law is shown in Fig. 20. Similarly, the results of CPA-HCl ion-associates with PA, PR and CPR correlated to Beer's law are presented in Fig. 21.


FIG. 20: CALIBRATION CURVES OF PZ-HCI ION-ASSOCIATES WITH PA, PR AND CPR


FIG. 21: CALIBRATION CURVES OF CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR

For PZ-HCl, the linear concentration ranges were found in the range 3.05-43.60, 8.72-104.64 and 3.27-49.05 $\mu \mathrm{g} / \mathrm{mL}$ with PA, PR and CPR reagents, respectively as shown in Table 2. The molar absorptivities ( $\varepsilon$ ) were calculated to be $1.105 \times 10^{4}, 4.212 \times 10^{3}$ and $9.624 \times$
$10^{3} \mathrm{~L} \mathrm{~mol}^{-1} \mathrm{~cm}^{-1}$ for PZ-HCl ion-associates with PA, PR and CPR reagents, respectively and also Sandell's sensitivities calculated to be $3.9 \times 10^{-2}, 10.4 \times 10^{-2}$ and $4.5 \times 10^{-2} \mu \mathrm{~g} \mathrm{~cm}^{-2}$ for PZ-HCl ion-associates with PA, PR and CPR reagents, respectively.

For $\mathrm{CPA}-\mathrm{HCl}$, the linear concentration ranges were found in the range 3.40-47.64, 8.51-88.48 and 3.40$40.84 \mu \mathrm{~g} / \mathrm{mL}$ with $\mathrm{PA}, \mathrm{PR}$ and CPR reagents, respectively as shown in Table 2. The molar absorptivities $(\varepsilon)$ were calculated to be $7.674 \times 10^{3}$, $3.718 \times 10^{3}$ and $8.617 \times 10^{3} \mathrm{~L} \mathrm{~mol}^{-1} \mathrm{~cm}^{-1}$ for CPA-HCl ion-associates with PA, PR and CPR reagents, respectively and also Sandell's sensitivities calculated to be $4.04 \times 10^{-2}, 9.2 \times 10^{-2}$ and $3.9 \times 10^{-2} \mu \mathrm{~g} \mathrm{~cm}^{-2}$ for CPA-HCl ion-associates with PA, PR and CPR reagents, respectively.

The regression equations $(Y=a+b C$ where $Y=$ absorbance, $\mathrm{a}=$ intercept, $\mathrm{b}=$ slope and $\mathrm{C}=$ concentration in $\mu \mathrm{g} / \mathrm{mL}$ ), calculated from the calibration graphs ( $\mathrm{N}=5$ ) using Kalied graph program, were evaluated and recorded in Table 2 for PZ-HCl and $\mathrm{CPA}-\mathrm{HCl}$. The intercepts of the lines were very small indicating that there is no systematic difference between the determined and expected concentrations within the investigated range using the current methods. The all RSD values from $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ were evaluated and recorded in Table 2. These data indicates that the developed methods have a good repeatability (were lower than 10\%).

The Limit of Detection (LOD) and Limit of Quantification (LOQ) of PZ-HCl and CPA-HCl by the proposed methods were determined using calibration curves and recorded in Table 2. [LOD and LOQ were calculated as $3.3 \mathrm{\sigma} / \mathrm{S}$ and $10 \mathrm{\sigma} / \mathrm{S}$, respectively, where S is the slope of the calibration curve and $\sigma$ is the standard deviation of $y$ - intercept of regression equation ${ }^{20}$.

TABLE 2: FEATURES OF THE CALIBRATION CURVES OF PZ-HCI AND CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR (N=5)

| Features | PZ-HCl |  |  | CPA-HCl |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Values for PA | Values for PR | Values for CPR | Values for PA | Values for PR | Values for CPR |
| Number of data points | 7 | 7 | 9 | 8 | 7 | 7 |
| Beer's law verification range, $\mu \mathrm{g} / \mathrm{mL}$ | 3.05-43.60 | 8.72-104.64 | 3.27-49.05 | 3.4-47.64 | 8.51-88.48 | 3.4-40.84 |
| Molar absorpitivity ( $\varepsilon$ ) $\left[\mathrm{L} \mathrm{mol}^{-1} \mathrm{~cm}^{-1}\right]$ | $1.105 \times 10^{4}$ | $4.212 \times 10^{3}$ | $9.624 \times 10^{3}$ | $7.674 \times 10^{3}$ | $3.718 \times 10^{3}$ | $8.617 \times 10^{3}$ |
| Sandell's sensitivity [ $\mu \mathrm{g} \mathrm{cm}{ }^{-2}$ ] | $3.9 \times 10^{-2}$ | $10.4 \times 10^{-2}$ | $4.5 \times 10^{-2}$ | $4.04 \times 10^{-2}$ | $9.2 \times 10^{-2}$ | $3.9 \times 10^{-2}$ |
| Regression equation ( $Y^{\text {a }}$ | $Y=a+b C$ | $Y=a+b C$ | $Y=a+b C$ | $Y=a+b C$ | $Y=a+b C$ | $Y=a+b C$ |
| Slope (b) | 0.0244 | 0.0097 | 0.0214 | 0.0216 | 0.0113 | 0.0247 |
| Intercept (a) | 0.008 | -0.002 | 0.007 | 0.010 | -0.006 | 0.007 |
| Correlation coefficient ( $\mathrm{r}^{2}$ ) | 0.9998 | 0.9995 | 0.9998 | 0.9998 | 0.9998 | 0.9999 |
| RSD ${ }^{\text {b) }}$ (\%) | 0.76-2.53 | 0.20-2.55 | 0.69-3.09 | 0.89-3.11 | 0.19-2.11 | 0.48-2.76 |
| Limit of Detection, LOD, $\mu \mathrm{g} / \mathrm{mL}$ | 0.40 | 0.75 | 0.38 | 0.53 | 1.04 | 0.51 |
| Limit of Quantification, LOQ, $\mu \mathrm{g} / \mathrm{mL}$ | 1.22 | 2.28 | 1.15 | 1.62 | 3.14 | 1.54 |

a) $\overline{Y=a+b C}$ (where $C$ is the concentration of analyte, $\mu \mathrm{g} / \mathrm{mL}$ and Y is absorbance), b) Calculated from five determinations.

Interferences study: To study the potential interference problems from the commonly used excipients and other additives which may be present in the pharmaceutical preparations such as microcrystalline cellulose, lactose, povidone, starch, magnesium stearate, sucrose and hydroxypropylmethylcellulose, recovery studies were out. Under the experimental conditions employed, excipients in different concentrations were added to a known amount of 9,20 and $9 \mu \mathrm{~g} / \mathrm{mL}$ for $\mathrm{PZ}-\mathrm{HCl}$ with $P A, P R$ and CPR, respectively and to a known amount of 9,16 and $8 \mu \mathrm{~g} / \mathrm{mL}$ for CPA- HCl with PA, PR and CPR, respectively and analyzed according to recommended procedures described earlier.

Results of the recovery analysis of PZ-HCl and CPA-HCl drugs and the above mentioned excipients are presented in Table 3. It was concluded that the excipients did not interfere with quantification of PZHCl and $\mathrm{CPA}-\mathrm{HCl}$ drugs in these methods and the proposed method could be considered specific. In addition recoveries in most cases were around 100\% and the lower values of the RSD indicate the good precision of the method, thus the procedures was able to determination of PZ-HCl and CPA-HCl drugs in the presence of excipients. In the proposed method, there were no needs for pre-separation and only centrifugation was applied to make the solution clear.

TABLE 3: DETERMINATION OF PZ-HCI AND CPA-HCI ION-ASSOCIATES WITH PA, PR AND CPR IN PRESENCE OF EXCIPIENTS (EACH VALUE IS A RESULT OF FIVE SEPARATE DETERMINATIONS)

| Excipients | Amount taken of PZ-HCl ( $\mu \mathrm{g} / \mathrm{mL}$ ) |  |  | Amount taken of CPA-HCI ( $\mu \mathrm{g} / \mathrm{mL}$ ) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 9 | 20 | 9 | 9 | 16 | 8 |
|  | $\begin{gathered} \text { \% Recovery } \pm \text { SD } \\ \text { PA } \end{gathered}$ | $\begin{gathered} \hline \text { \% Recovery } \pm \text { SD } \\ \text { PR } \end{gathered}$ | \% Recovery $\pm$ SD CPR | $\begin{gathered} \hline \text { \% Recovery } \pm \text { SD } \\ \text { PA } \end{gathered}$ | $\begin{gathered} \hline \text { \% Recovery } \pm \text { SD } \\ \text { PR } \end{gathered}$ | \% Recovery $\pm$ SD CPR |
| Microcrystalline cellulose | $99.55 \pm 1.42$ | $99.33 \pm 0.93$ | $100.18 \pm 0.95$ | $99.70 \pm 0.36$ | $99.62 \pm 0.39$ | $99.80 \pm 1.42$ |
| Lactose | $99.33 \pm 0.62$ | $100.03 \pm 1.57$ | $99.70 \pm 1.079$ | $99.45 \pm 0.69$ | $100.17 \pm 1.24$ | $100.59 \pm 1.44$ |
| Povidone | $100.04 \pm 0.84$ | $99.95 \pm 1.05$ | $100.15 \pm 0.84$ | $100.44 \pm 1.02$ | $100.42 \pm 0.97$ | $99.96 \pm 1.37$ |
| Starch | $99.44 \pm 0.62$ | $99.97 \pm 1.42$ | $100.15 \pm 0.74$ | $99.45 \pm 0.80$ | $100.23 \pm 1.09$ | $100.17 \pm 1.21$ |
| Magnesium stearate | $100.41 \pm 1.63$ | $99.32 \pm 0.67$ | $99.33 \pm 0.55$ | $100.15 \pm 1.62$ | $99.96 \pm 1.10$ | $100.71 \pm 0.44$ |
| Sucrose | $100.78 \pm 1.06$ | $100.13 \pm 0.60$ | $100.18 \pm 1.11$ | $100.07 \pm 1.079$ | $100.13 \pm 1.66$ | $100.13 \pm 1.88$ |
| Glucose | $99.00 \pm 0.73$ | $99.72 \pm 0.86$ | $99.70 \pm 0.74$ | $100.30 \pm 1.45$ | $99.37 \pm 1.38$ | $99.75 \pm 1.39$ |
| Hydroxypropyl methylcellulose | $100.52 \pm 1.07$ | $99.55 \pm 0.70$ | $99.93 \pm 1.11$ | $99.89 \pm 1.35$ | $99.58 \pm 0.51$ | $100.09 \pm 1.58$ |

Analysis of tablets: Recovery studies were performed to judge the accuracy of the proposed method. Five replicate determinations, using selected reagents, three different concentrations of pure $\mathrm{PZ}-\mathrm{HCl}$ and
selgon 20 mg /tablet as well as for pure CPA-HCl and allergex $20 \mathrm{mg} /$ tablet were investigated. [From the amount of drug found, percentage recovery was calculated and accuracy was assessed as the
percentage relative error (Bias \%) between the measured mean concentrations and added concentrations at the same concentration of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$. And then, the results of the accuracy and recovery studies of PZ-HCl and $\mathrm{CPA}-\mathrm{HCl}$ in their pure forms and their tablet dosage forms are summarized in Table 4.

To give additional support to accuracy of the developed assay method, standard addition method was done. In this study, three different concentrations of pure PZ-HCl and CPA-HCl drugs with PA, PR and CPR reagents, respectively were added to a known preanalyzed formulation samples (PZ-HCl and $\mathrm{CPA}-\mathrm{HCl}$ tablets) and the total concentrations were determined using the proposed methods ( $n=5$ ).

The percent recovery of the added pure drug was calculated as, \% recovery $=\left[\left(C_{v}-C_{u}\right) / C_{a}\right] \times 100$, where $C_{v}$ is the total drug concentration measured after standard addition, $\mathrm{C}_{\mathrm{u}}$ is drug concentration in the TABLE 4: ACCURACY AND RECOVERY DATA FOR THE DEVELOPED METHODS (EACH VALUE IS A RESULT OF FIVE SEPARATE DETERMINATIONS)

| Drug | Sample | Method | Predicted con. ( $\mu \mathrm{g} / \mathrm{mL})^{\text {a }}$ |  |  | Mean <br> \% recovery ( $\pm$ S.D) | Accuracy (\%) ${ }^{\text {b }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Range | Mean ( $\pm$ S.D) | \% R.S.D |  |  |
| PZ-HCl | Pure solution | PA | 08.85-09.21 | 09.05 $\pm 0.14$ | 1.60 | $100.51 \pm 1.61$ | 0.51 |
|  |  |  | 17.73-18.30 | $18.06 \pm 0.25$ | 1.36 | $100.36 \pm 1.37$ | 0.36 |
|  |  |  | 31.54-32.21 | $31.88 \pm 0.27$ | 0.84 | $99.62 \pm 0.84$ | -0.38 |
|  |  | PR | 19.73-20.20 | $19.95 \pm 0.19$ | 0.94 | $99.73 \pm 0.93$ | -0.27 |
|  |  |  | 39.49-40.31 | $39.99 \pm 0.31$ | 0.79 | $99.98 \pm 0.79$ | -0.02 |
|  |  |  | 79.66-80.22 | $79.96 \pm 0.25$ | 0.31 | $99.95 \pm 0.31$ | -0.05 |
|  |  | CPR | 08.85-09.25 | $9.02 \pm 0.16$ | 1.75 | $100.20 \pm 1.76$ | 0.20 |
|  |  |  | 17.77-18.22 | $17.97 \pm 0.19$ | 1.04 | $99.86 \pm 1.03$ | -0.14 |
|  |  |  | 35.55-36.16 | $35.92 \pm 0.27$ | 0.75 | $99.78 \pm 0.75$ | -0.22 |
|  | Selgon Tablet | PA | 08.74-09.15 | $8.99 \pm 0.16$ | 1.79 | $99.93 \pm 1.79$ | -0.07 |
|  |  |  | 17.65-18.15 | $17.93 \pm 0.19$ | 1.06 | $99.63 \pm 1.06$ | -0.37 |
|  |  |  | 31.52-32.08 | $31.79 \pm 0.21$ | 0.66 | $99.36 \pm 0.65$ | -0.64 |
|  |  | PR | 19.65-20.20 | $19.91 \pm 0.24$ | 1.20 | $99.55 \pm 1.19$ | -0.45 |
|  |  |  | 39.29-40.21 | $39.77 \pm 0.38$ | 0.97 | $99.44 \pm 0.96$ | -0.57 |
|  |  |  | 79.31-80.05 | $79.69 \pm 0.29$ | 0.37 | $99.62 \pm 0.36$ | -0.38 |
|  |  | CPR | 08.85-09.16 | 08.99 $\pm 0.13$ | 1.38 | $99.84 \pm 1.38$ | -0.16 |
|  |  |  | 17.59-18.1 | $17.90 \pm 0.19$ | 1.08 | $99.45 \pm 1.07$ | -0.56 |
|  |  |  | 35.48-36.14 | $35.74 \pm 0.26$ | 0.73 | $99.29 \pm 0.72$ | -0.71 |
| CPA-HCl | Pure solution | PA | 08.84-09.14 | 09.01 $\pm 0.13$ | 1.41 | $100.09 \pm 1.41$ | 0.09 |
|  |  |  | 17.69-18.22 | $17.92 \pm 0.19$ | 1.08 | $99.54 \pm 1.073$ | -0.46 |
|  |  |  | 35.69-36.21 | 36.01士0.22 | 0.61 | $100.03 \pm 0.61$ | 0.03 |
|  |  | PR | 15.69-16.17 | $15.92 \pm 0.19$ | 1.17 | $99.49 \pm 1.17$ | -0.51 |
|  |  |  | 31.46-32.20 | $31.89 \pm 0.31$ | 0.97 | $99.67 \pm 0.97$ | -0.33 |
|  |  |  | 63.52-64.31 | $63.95 \pm 0.38$ | 0.60 | $99.93 \pm 0.60$ | -0.08 |


|  | CPR | $\begin{aligned} & \text { 07.91-08.21 } \\ & 15.74-16.10 \\ & 31.69-32.25 \end{aligned}$ | $\begin{aligned} & 08.05 \pm 0.12 \\ & 15.92 \pm 0.15 \\ & 31.97 \pm 0.22 \end{aligned}$ | $\begin{aligned} & 1.53 \\ & 0.93 \\ & 0.69 \end{aligned}$ | $\begin{gathered} 100.58 \pm 1.54 \\ 99.5 \pm 0.93 \\ 99.89 \pm 0.69 \end{gathered}$ | $\begin{gathered} 0.58 \\ -0.5 \\ -0.11 \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Allergex <br> Tablets | PA | $\begin{aligned} & 08.79-09.08 \\ & 17.59-18.21 \\ & 35.56-36.25 \end{aligned}$ | $\begin{aligned} & 08.95 \pm 0.11 \\ & 17.89 \pm 0.25 \\ & 35.88 \pm 0.29 \end{aligned}$ | $\begin{aligned} & 1.24 \\ & 1.37 \\ & 0.81 \end{aligned}$ | $\begin{gathered} 99.4 \pm 1.23 \\ 99.38 \pm 1.36 \\ 99.67 \pm 0.80 \end{gathered}$ | $\begin{aligned} & -0.60 \\ & -0.62 \\ & -0.33 \end{aligned}$ |
|  | PR | $\begin{aligned} & 15.52-16.10 \\ & 31.51-32.19 \\ & 63.31-64.08 \end{aligned}$ | $\begin{aligned} & 15.89 \pm 0.25 \\ & 31.87 \pm 0.29 \\ & 63.64 \pm 0.37 \end{aligned}$ | $\begin{aligned} & 1.55 \\ & 0.90 \\ & 0.58 \end{aligned}$ | $\begin{gathered} 99.3 \pm 1.54 \\ 99.58 \pm 0.90 \\ 99.44 \pm 0.58 \end{gathered}$ | $\begin{aligned} & -0.70 \\ & -0.42 \\ & -0.56 \end{aligned}$ |
|  | CPR | $\begin{aligned} & \hline 07.81-08.12 \\ & 15.72-16.22 \\ & 31.59-32.26 \end{aligned}$ | $\begin{aligned} & \hline 09.95 \pm 0.13 \\ & 15.96 \pm 0.20 \\ & 31.87 \pm 0.29 \end{aligned}$ | $\begin{aligned} & 1.61 \\ & 1.25 \\ & 0.92 \end{aligned}$ | $\begin{gathered} 99.3 \pm 1.60 \\ 99.76 \pm 1.25 \\ 99.61 \pm 0.92 \end{gathered}$ | $\begin{aligned} & \hline-0.70 \\ & -0.24 \\ & -0.34 \end{aligned}$ |

${ }^{a}$ Predicted concentration of PZ-HCl and CPA-HCl with PA, PR and CPR were calculated by linear regression equation.
${ }^{\mathrm{b}}$ Accuracy is given in \% relative error (=100×[(predicted concentration-nominal concentration) / nominal concentration)].
TABLE 5: RESULTS OF STANDARD ADDITION METHOD FOR PZ-HCI AND CPA-HCI WITH PA, PR AND CPR (EACH VALUE IS A RESULT OF FIVE SEPARATE DETERMINATIONS)

|  | PZ-HCl |  |  |  | CPA-HCI |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Method | Conc. of drug In tablets ( $\mu \mathrm{g} / \mathrm{mL}$ ) | Conc. of pure drug added ( $\mu \mathrm{g} / \mathrm{mL}$ ) | Total conc. of drug found ( $\mu \mathrm{g} / \mathrm{mL}$ ) | \% Analytical Recovery ( $\pm$ S.D) | Conc. of drug in tablets ( $\mu \mathrm{g} / \mathrm{mL}$ ) | Conc. of pure drug added ( $\mu \mathrm{g} / \mathrm{mL}$ ) | Total conc. of drug found ( $\mu \mathrm{g} / \mathrm{mL}$ ) | \% Analytical recovery ( $\pm$ S.D) |
| PA | $\begin{aligned} & 08.95 \\ & 08.95 \\ & 08.95 \end{aligned}$ | $\begin{aligned} & 09.00 \\ & 18.00 \\ & 32.00 \end{aligned}$ | $\begin{aligned} & 17.96 \\ & 26.90 \\ & 40.78 \end{aligned}$ | $\begin{gathered} 100.11 \pm 1.97 \\ 99.72 \pm 1.33 \\ 99.46 \pm 0.55 \end{gathered}$ | $\begin{aligned} & 08.94 \\ & 08.94 \\ & 08.94 \end{aligned}$ | $\begin{aligned} & 09.00 \\ & 18.00 \\ & 36.00 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17.95 \\ & 26.85 \\ & 44.80 \end{aligned}$ | $\begin{gathered} 100.03 \pm 1.17 \\ 99.49 \pm 1.20 \\ 99.62 \pm 0.83 \end{gathered}$ |
| PR | $\begin{aligned} & 19.86 \\ & 19.86 \\ & 19.86 \end{aligned}$ | $\begin{aligned} & 20.00 \\ & 40.00 \\ & 80.00 \end{aligned}$ | $\begin{aligned} & 39.77 \\ & 59.75 \\ & 99.51 \end{aligned}$ | $\begin{aligned} & 99.54 \pm 1.28 \\ & 99.74 \pm 0.86 \\ & 99.68 \pm 0.81 \end{aligned}$ | $\begin{aligned} & 15.90 \\ & 15.90 \\ & 15.90 \end{aligned}$ | $\begin{aligned} & 16.00 \\ & 32.00 \\ & 64.00 \end{aligned}$ | $\begin{aligned} & 31.79 \\ & 47.89 \\ & 79.61 \end{aligned}$ | $\begin{aligned} & 99.30 \pm 1.68 \\ & 99.76 \pm 1.19 \\ & 99.54 \pm 0.79 \end{aligned}$ |
| CPR | $\begin{aligned} & \hline 08.94 \\ & 08.94 \\ & 08.94 \end{aligned}$ | $\begin{aligned} & \hline 09.00 \\ & 18.00 \\ & 36.00 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17.90 \\ & 26.82 \\ & 44.72 \end{aligned}$ | $\begin{aligned} & 99.58 \pm 1.51 \\ & 99.22 \pm 1.61 \\ & 99.38 \pm 0.86 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 07.94 \\ & 07.94 \\ & 07.94 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 08.00 \\ & 16.00 \\ & 32.00 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15.95 \\ & 23.89 \\ & 39.84 \\ & \hline \end{aligned}$ | $\begin{gathered} 100.18 \pm 1.48 \\ 99.67 \pm 1.51 \\ 99.68 \pm 0.87 \\ \hline \end{gathered}$ |

The percent recovery of the added pure drug was calculated as, $\%$ recovery $=\left[\left(C_{v}-C_{u}\right) / C_{a}\right] \times 100$, where $C_{v}$ is the total drug concentration measured after standard addition; $\mathrm{C}_{\mathrm{u}}$, drug concentration in the formulation; $\mathrm{C}_{\mathrm{a}}$, drug concentration added to formulation

TABLE 6: STATISTICAL EVALUATIONS OF OBTAINED DATA FROM PZ-HCI AND CPA-HCI (PURE DRUGS) AND PHARMACEUTICAL FORMULATION (TABLETS) CONTAINING PZ-HCI AND CPA-HCI BY THE PROPOSED AND REFERENCE METHODS

| Statistical values | PZ-HCl <br> Pure solution |  |  | ${ }^{21}$ Ref. method | PZ-HCl <br> Selgon Tablets |  |  | ${ }^{21}$ Ref. method | CPA-HCI Pure solution |  |  | ${ }^{21}$ Ref. method | CPA-HCl <br> Allergex Tablets |  |  | ${ }^{21}$ Ref. method |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | PA | PR | CPR |  | PA | PR | CPR |  | PA | PR | CPR |  | PA | PR | CPR |  |
| N | 5 | 5 | 5 | 3 | 5 | 5 | 5 | 3 | 5 | 5 | 5 | 3 | 5 | 5 | 5 | 3 |
| $\mathrm{X}^{-}$, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Recovery (\%) | 100.16 | 99.89 | 99.95 | 100.22 | 99.64 | 99.54 | 99.53 | 99.95 | 99.89 | 99.69 | 99.99 | 100.31 | 99.48 | 99.44 | 99.56 | 99.39 |
| S.D. | 1.28 | 0.68 | 1.177 | 0.66 | 1.19 | 0.85 | 1.04 | 0.58 | 1.03 | 0.89 | 1.13 | 0.54 | 1.08 | 1.01 | 1.21 | 0.69 |
| R.S.D. (\%) | 1.28 | 0.68 | 1.177 | 0.66 | 1.20 | 0.85 | 1.04 | 0.58 | 1.03 | 0.90 | 1.13 | 0.54 | 1.09 | 1.02 | 1.21 | 0.70 |
| F- value: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $F^{\text {c }}$ | 3.73 | 1.07 | 3.16 |  | 4.25 | 2.14 | 3.22 |  | 3.63 | 2.71 | 4.35 |  | 2.44 | 2.12 | 3.04 |  |
| $F^{t}$ <br> t-value: | 6.94 | 6.94 | 6.94 |  | 6.94 | 6.94 | 6.94 |  | 6.94 | 6.94 | 6.94 |  | 6.94 | 6.94 | 6.94 |  |
| $t^{\text {c }}$ | 0.10 | 1.08 | 0.51 |  | 0.58 | 1.08 | 0.90 |  | 0.91 | 1.56 | 0.63 |  | 0.19 | 0.11 | 0.31 |  |
| $t^{\text {t }}$ | 2.77 | 2.77 | 2.77 |  | 2.77 | 2.77 | 2.77 |  | 2.77 | 2.77 | 2.77 |  | 2.77 | 2.77 | 2.77 |  |

N : number of determination, $\mathrm{X}^{-}$: mean recovery, S.D: standard deviation, F -value and t -value are theoretical values at $95 \%$ confidence level, $\mathrm{F}^{\mathrm{c}}$ : calculated $F$-value, $F^{t}$ : tabulated $F$-value, $t^{c}$ : calculated $t$-value, $t^{t}$ : tabulated $t$-value.

CONCLUSION: The proposed methods $A, B$ and $C$ are simple, rapid, precise, accurate and sensitive compared to the reported methods. The utility of the proposed methods for the determination of $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ compounds in their pure forms and their tablet dosage forms have been well demonstrated. The assay methods did not involve any stringent experimental conditions, and were also free from interference by common excipients. The mean values obtained and the calculated standard deviations are compared with those obtained by the reference methods, by applying the t- and F-tests. The results presented herein for $\mathrm{PZ}-\mathrm{HCl}$ and $\mathrm{CPA}-\mathrm{HCl}$ express excellent agreement and considered significant with those obtained using reference methods.

Hence, the proposed methods could be used for routine quality control. Thus, it clear that the present methods are of high accuracy, precision, speed and selectivity, beside being of low cost and easily applied for the determination of the drugs under investigation in pure form and tablet dosage form depend on simpler spectrophotometric measurements in visible region using chemical reagents which are available.

## REFERENCES:

1. Rahway NJ: The Merck Index, an Encyclopedia of Chemicals, Drugs and Biologicals Merck, USA, $13{ }^{\text {th }}$ (Ed) 2001.
2. Sweetman S (Ed.) Martindale: The complete drug reference, Pharmaceutical press. Electronic version: London, 2006.
3. Revanasiddappa HD and Ramappa PG: Reverse-phase highperformance liquid-chromatographic determination of pipazethate hydrochloride and thioproperazine mesylate in tablets. Indian Drugs 1995; 32:534-536.
4. Amin AS, El Sheikh R, Zahran $F$ and Gouda AA: Spectrophotometric determination of pipazethate HCl , dextromethorphan HBr and drotaverine HCl in their pharmaceutical preparations. Spectrochimica Acta 2007; 67:1088-1093.
5. El Sheikh R, Zahran $F$ and Gouda AA: Spectrophotometric determination of some anti-tussive and anti-spasmodic drugs through ion-pair complex formation with thiocyanate and
cobalt(II) or molybdenum(V). Spectrochimica Acta 2007; 66:1279-1287.
6. Issa YM, Shoukry AF and El Nashar RM: Conductimetric determination of reproterol HCl and pipazethate HCl and salbutamol sulphate in their pharmaceutical formulations. J Pharma Biomed Anal 2001; 3:379-386.
7. Bebawy LI and El-Kousy NM: Simultaneous determination of some multicomponent dosage forms by quantitative thin layer chromatography densitometric method. J Pharma. Biomed Anal 1999; 20:663-670.
8. Hassan WS, El Henawee MM and Gouda AA: Spectrophotometric determination of some histamine H1antagonists drugs in their pharmaceutical preparations. Spectrochimica Acta 2008; 69:245-255.
9. Dinç E, Palabıyık M, Üstünda Ö, Yurtsever F and Onur F: Simultaneous spectrophotometric determination of chlorphenoxamine hydrochloride and caffeine in a pharmaceutical preparation using first derivative of the ratio spectra and chemometric methods. J Pharma Biomed Anal 2002; 28:591-600.
10. Amin AS and El Henawee MM: Colorimetric method for the simultaneous determination of chlorphenoxamine hydrochloride and anhydrous caffeine in pure and dosage forms with Rose Bengal. Microchim Acta 1995; 118:177-183.
11. Ayad M, Saleh H, El Maamli M, El-Bolkiny M and El Henawee M: Determination of certain antihistamines through ternary complex formation. Anal Lett 1993; 26:913-923.
12. El Henawee MM, Mohamed HS, El Bolkiny N and Ayad MM: UV derivative spectrophotometric determination of chlorphenoxamine hydrochloride in combination with anhydrous caffeine. Spectrosc Lett 1990; 23:273-282.
13. Issa YM and Amin AS: Analytical application of atomicabsorption spectrometry for the determination of chlorpheniramine maleate and chlorphenoxamine.hydrochloride in pure form and in pharmaceutical preparations. Analysis 1996; 24:139-142.
14. Temizer A and Ozaltin N: Polarographic determination of antihistamines by complexation with cadmium(II). J Assoc of Anal Chem 1986; 69:192-195.
15. Yoe JH and Jones AL: Ind Eng Chem Anal (Ed) 16, 1944:14.
16. Job P: Camp Rend (Paris), 180, 1925:928; Ann Chim (Paris), 9, 1928:133; Ann Chim (Paris), 6, 1936:97.
17. Vosburgh WC and Cooper GP: J Am Chem Soc 1941; 63:437.
18. Schnur DM, Yuh YH and Dalton DR: J Org Chem 1989; 54:3779.
19. Allinger NL: J Comput Chem 1993; 14:755.
20. Validation of Analytical Procedure Methodology ICH Harmonized Tripartite Guidelines.1996:1.
21. Gaur R, Azizi M, Gan J, Hansal P, Harper K, Mannan R, Panchal A, Patel K, Patel M, Patel N, Rana J and Rogowska A: British Pharmacopoeia. HerMajasty's, Stationary Office, London, 2009.
22. Dowdy S, Weardern S and Wiley NY: Statistics for Research, 1983.
